Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

Almost a third (31%) of women with low-grade serous ovarian cancer, which does not respond well to chemotherapy, saw their ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

A groundbreaking study has uncovered the origin of one of the most aggressive forms of ovarian cancer, called high-grade ...

The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ...

Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

They found serous tubal intraepithelial carcinoma (STIC), a precancerous lesion, in uterine serous carcinoma and serous ovarian carcinoma but not in nonserous uterine cancer or benign conditions.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian ...

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.